Project Grant R61NS131303
Award Date
8/5/24
Completion Date
7/31/26
Dollars Obligated
$1.6M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...
This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
This federal Project Grant awarded by the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), aims to develop a safe and effective topically administered pharmacotherapy to treat acute corneal pain. The $590,172 award to Vyluma Inc., with a period of performance from Sep 30, 2024 to Aug 31, 2025, will support three specific research aims: 1) a pharmacodynamic dose identification study to determine the minimum effective dose of the pregabalin-based...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $603,406 to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medicines and reducing opioid-related side effects. The project aims to optimize potency, selectivity, and drug-like properties of GPR139...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
This $1,563,778 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279) on September 12, 2024. The grant supports research conducted by Duke University to develop equilibrative nucleoside transporter (ENT1) inhibitors as potential non-opioid pain therapeutics. The project aims to: 1) validate ENT1 as a novel target for neuropathic pain treatment, 2) characterize a novel ENT1 inhibitor compound...
This $1,656,000 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the Scripps Research Institute to investigate the role of endogenous opioid signaling in regulating neuro-immune interactions and immune homeostasis in the skin. The 4-year project seeks to uncover how sensory neurons and immune cells, particularly regulatory T...
The National Eye Institute (NEI) awarded a $578,123 Project Grant (CFDA 93.867 - Vision Research) to the Regents of the University of Michigan to conduct a comprehensive study on central nervous system mechanisms and treatment response in chronic ocular surface pain (COSP). The 5-year research project aims to rigorously define the role of nociplastic (centralized) pain in COSP, which affects 5-15% of the U.S. population at an estimated annual cost of over $55 billion. The study will utilize...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...